Amedisys, Inc. (NASDAQ:AMED – Get Rating) insider Denise M. Bohnert sold 557 shares of the stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $115.00, for a total value of $64,055.00. Following the sale, the insider now owns 11,850 shares in the company, valued at approximately $1,362,750. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Shares of AMED opened at $114.60 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $3.73 billion, a P/E ratio of 19.72, a price-to-earnings-growth ratio of 2.26 and a beta of 0.89. The stock’s fifty day simple moving average is $121.03 and its 200 day simple moving average is $141.54. Amedisys, Inc. has a twelve month low of $101.61 and a twelve month high of $276.21.
Amedisys (NASDAQ:AMED – Get Rating) last issued its earnings results on Wednesday, April 27th. The health services provider reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.12. The business had revenue of $545.26 million for the quarter, compared to analyst estimates of $557.81 million. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. During the same period last year, the company posted $1.54 EPS. Sell-side analysts predict that Amedisys, Inc. will post 5.29 earnings per share for the current year.
A number of equities research analysts have commented on AMED shares. Truist Financial lowered their target price on Amedisys from $200.00 to $175.00 and set a “buy” rating on the stock in a report on Tuesday, June 21st. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 target price on shares of Amedisys in a report on Thursday, April 7th. SVB Leerink lowered their target price on Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a report on Tuesday, June 21st. Oppenheimer reissued an “outperform” rating and set a $200.00 price target on shares of Amedisys in a research note on Friday, April 29th. Finally, Raymond James reduced their price target on Amedisys from $200.00 to $180.00 in a research note on Friday, April 29th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $173.27.
Several institutional investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Amedisys by 55.3% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock valued at $38,000 after acquiring an additional 83 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of Amedisys by 2.5% during the first quarter. Prudential Financial Inc. now owns 3,728 shares of the health services provider’s stock valued at $643,000 after acquiring an additional 90 shares in the last quarter. Van ECK Associates Corp grew its stake in Amedisys by 13.6% in the fourth quarter. Van ECK Associates Corp now owns 775 shares of the health services provider’s stock worth $125,000 after purchasing an additional 93 shares in the last quarter. Truist Financial Corp grew its stake in Amedisys by 3.6% in the first quarter. Truist Financial Corp now owns 2,698 shares of the health services provider’s stock worth $465,000 after purchasing an additional 93 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its stake in Amedisys by 1.2% in the fourth quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the health services provider’s stock worth $1,360,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 90.47% of the company’s stock.
About Amedisys (Get Rating)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Recommended Stories
Receive News & Ratings for Amedisys Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amedisys and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net